Climate Change Data

argenx SE

Climate Impact & Sustainability Data (2022, 2023)

Reporting Period: 2022

Environmental Metrics

Renewable Energy Share:50% (Ghent site)
Total Energy Consumption:754,979 kWh/year
Waste Generated:15,060 kg/year

ESG Focus Areas

  • Patients
  • People
  • Governance
  • Planet

Environmental Achievements

  • Began measuring energy consumption, non-renewable energy use, waste, and water usage at its Ghent site.
  • Achieved 100% recycling of paper, cardboard, hard plastics, foils, glass, and aluminum, as well as 100% recycling of electronic waste at its Ghent site.
  • Implemented programs to encourage low-carbon commuting to its Ghent site.
  • Implemented a policy supporting a hybrid and flexible working environment to reduce commuting.

Social Achievements

  • Launched MG United, a global lifestyle platform for the myasthenia gravis (MG) community.
  • Partnered with patient organizations to launch MyRealWorldMG, a real-world evidence study on MG.
  • Supported the creation of an annual European Union MG Day.
  • Achieved zero safety incidents for the fourth consecutive year.
  • Expanded its Buddy Program to help new employees integrate.
  • Developed Personal Development Plans (PDPs) to maximize employee strengths.
  • Made progress toward gender balance in leadership (39% women).

Governance Achievements

  • Diversified its Board of Directors, adding three new directors.
  • Complied with the best practice principles set out in the Dutch Corporate Governance Code, with exceptions related to remuneration policy (explained in the Annual Report).
  • Conducted an education session for Board members on ESG.
  • Established a cross-functional ESG working group.
  • 100% of argonauts completed annual Code of Business Conduct and Ethics training.

Climate Goals & Targets

Short-term Goals:
  • Achieve Green Lab Certification for Ghent site.

Environmental Challenges

  • Measuring and managing environmental impact across all sites.
  • Ensuring diversity in clinical trials for rare diseases.
  • Maintaining data security and privacy across a global organization.
  • Managing waste and hazardous materials in its operations.
Mitigation Strategies
  • Started measuring key environmental metrics at its main site.
  • Implemented proactive outreach, education, and accessibility measures for clinical trials.
  • Adopted GDPR as its overall privacy standard and implemented ISO 27001-based ISMS.
  • Implemented color-coded waste bins and partnered with waste management companies for processing.

Supply Chain Management

Supplier Audits: 100% of vendors involved in manufacturing, testing, and distribution audited in 2022

Responsible Procurement
  • Engaging with top suppliers to ensure alignment with environmental, health, and safety policies.

Climate-Related Risks & Opportunities

Opportunities
  • Reducing energy costs through improved storage and transport conditions.

Reporting Standards

Frameworks Used: SASB

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:433,347 tCO2e (location-based)
Scope 1 Emissions:378 tCO2e
Scope 2 Emissions:183 tCO2e (location-based), 189 tCO2e (market-based)
Scope 3 Emissions:432,786 tCO2e
Total Energy Consumption:814,362 kWh (Zwijnaarde), 39,177 kWh (Tokyo), 87,108 kWh (Boston)
Water Consumption:52,427 m3 (Zwijnaarde)
Waste Generated:12,400 kg (Tokyo), 11,750 kg (Zwijnaarde)
Carbon Intensity:0.0004 tCO2e/$ (location-based and market-based)

ESG Focus Areas

  • Patients
  • People
  • Governance
  • Planet

Environmental Achievements

  • Calculated GHG emissions for the first time in 2023 (433,347 tCO2e location-based; 433,353 tCO2e market-based).

Social Achievements

  • Achieved 0 workplace accidents or injuries for the fifth consecutive year.
  • Voluntary employee turnover rate of 5% and involuntary turnover rate of 2%, below industry standards.
  • More than 25 patient panels and listening sessions held in 10 countries.
  • Launched the podcast “Untold Stories: Life with Myasthenia Gravis,” reaching 97,000 downloads.

Governance Achievements

  • Complied with best practice principles set out in the Dutch Corporate Governance Code (except for certain principles relating to remuneration policy).
  • 99.4% of employees completed Code of Business Conduct and Anti-Bribery Policy training.

Climate Goals & Targets

Environmental Challenges

  • Ensuring diverse enrollment in clinical trials for rare diseases.
  • Managing GHG emissions across global operations.
Mitigation Strategies
  • Proactive outreach, patient education, and accessibility considerations in clinical trials.
  • Implemented GHG Protocol for emissions calculation and will adapt methodologies in future reporting years.

Supply Chain Management

Supplier Audits: 100% of planned audits completed

Responsible Procurement
  • Collaboration with Lonza and Fujifilm for manufacturing.
  • Adherence to FDA's current good manufacturing practices.
  • Participation in Rx-360 audit program.

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: SASB Standards for Biotechnology & Pharmaceuticals